1. Home
  2. JANX
  3. Earnings

AI Earnings Predictions for Janux Therapeutics Inc. (JANX)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-1.05%

$17.99

0% positive prob.

5-Day Prediction

-6.54%

$16.99

0% positive prob.

20-Day Prediction

-5.61%

$17.16

0% positive prob.

Price at prediction: $18.18 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -1.05% -6.54% -5.61% 100.0% Pending
Q2 2026 BUY +3.63% +11.53% +9.96% 100.0% Pending
Q1 2026 SELL -0.81% -7.78% -8.50% 100.0% -1.03%
Q4 2025 SELL -0.81% -7.78% -8.50% 100.0% +1.23%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

-1.05%

$17.99

Act: +9.81%

5D

-6.54%

$16.99

20D

-5.61%

$17.16

Price: $18.18 Prob +5D: 0% AUC: 1.000
0001193125-26-449790

EX-99.1

2 janx-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

• Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026

• First patient dosed in the Phase 1 study evaluating JANX013 in combination with JANX007

• JANX007 Phase 1b development continues across taxane-naïve monotherapy and darolutamide combination cohorts

• JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)

• Strong balance sheet with $945.7 million in cash, cash equivalents and short-term investments supports advancement of multiple clinical-stage programs

SAN DIEGO, November 5, 2026 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update.

“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”

BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS:

Clinical and Pipeline Progress

• JANX007 (PSMA-TRACTr) continues to advance through Phase 1b development in metastatic castration-resistant prostate cancer (mCRPC), with ongoing dose optimization and expansion in taxane-naïve patients, including an actively enrolling cohort evaluating JANX007 in combination with darolutamide.

• JANX014 (PSMA-TRACTr), a double-masked, PSMA-targeted tumor-activated T-cell engager, continues enrollment in its Phase 1 clinical study evaluating safety, pharmacokinetics and preliminary antitumor activity in patients with mCRPC.

• JANX011 (CD19-ARM) continues to be evaluated in a Phase 1 clinical study in healthy volunteers. JANX011 is Janux's first clinical candidate from its Adaptive Immune Response Modulator (ARM) platform and was designed to achieve deep and durable B-cell depletion while limiting cytokine release. Initial clinical data from the study will be presented during an investor webcast on November 9, 2026.

• Janux recently disclosed that JANX011 selectively engages TRBV6-expressing T cells rather than broadly engaging the CD3+ T cell population, a differentiated approach intended to focus immune activation on a defined T cell subset.

• JANX013 (PSMA-TRACIr) The first patient has been dosed in the Phase 1 study evaluating JANX013 in combination with JANX007 in patients with mCRPC, representing the first clinical evaluation of Janux's TRACIr platform.

Upcoming Milestones

• Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 will be presented during an investor webcast, providing the first clinical evaluation of Janux's ARM platform.

• Additional clinical data from the Phase 1b study of JANX007 are expected to be presented at a medical congress in the first half of 2027.

THIRD QUARTER 2026 FINANCIAL RESULTS:

• Cash and cash equivalents and short-term investments: As of September 30, 2026, Janux reported cash and cash equivalents and short-term investments of $945.7 million, compared to $966.6 million as of December 31, 2025.

• Research and development expenses: Research and development expenses were $30.6 million for the quarter ended September 30, 2026, compared to $34.6 million for the comparable period in 2025.

• General and administrative expenses: General and administrative expenses were $10.0 million for the quarter ended September 30, 2026, compared to $10.6 million for the comparable period in 2025.

• Net loss: Net loss was $21.6 million for the quarter ended September 30, 2026, compared to $24.3 million for the comparable period in 2025.

About Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.

Janux’s lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA-TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr designed for combination with JANX007 and being evaluated in a Phase 1 clinical trial.

Beyond i

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 100% conf.

AI Prediction BUY

1D

+3.63%

$16.69

Act: -1.55%

5D

+11.53%

$17.96

20D

+9.96%

$17.70

Price: $16.10 Prob +5D: 100% AUC: 1.000
0001193125-26-337977

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786388482.cf8a252c

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-0.81%

$14.42

Act: -2.61%

5D

-7.78%

$13.41

Act: -1.03%

20D

-8.50%

$13.30

Act: -8.12%

Price: $14.54 Prob +5D: 0% AUC: 1.000
0001193125-26-211964

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784333922.4286de21

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About Janux Therapeutics Inc. (JANX) Earnings

This page provides Janux Therapeutics Inc. (JANX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on JANX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: